These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10999096)

  • 1. Management of anemia of chronic renal failure.
    Singh NP; Anuradha S; Chandrashekhar ; Agarwal SK
    J Assoc Physicians India; 1999 Feb; 47(2):216-23. PubMed ID: 10999096
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to EPO therapy.
    Bommer J
    Przegl Lek; 1992; 49(1-2):36-7. PubMed ID: 1455003
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment with low doses of intravenous iron does not modify hemoglobin nor the erythropoietin dosage].
    Fernández-Gallego J; Martín MA; Alonso A; Toledo R
    Nefrologia; 2006; 26(1):143-4. PubMed ID: 16649439
    [No Abstract]   [Full Text] [Related]  

  • 4. [Our experiences in the treatment of anemia in patients on regular renal dialysis].
    Lachmanová J; Klener P; Tomásek R; Kasparová B
    Cas Lek Cesk; 1975 Nov; 114(48):1480-3. PubMed ID: 1203933
    [No Abstract]   [Full Text] [Related]  

  • 5. [Iron therapy in patients in the chronic intermittent hemodialysis program (CHIHP)].
    Chrobák L; Radochová D; Erben J; Strnad L; Rouchal J
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl; 1981; 24(2):173-91. PubMed ID: 6975987
    [No Abstract]   [Full Text] [Related]  

  • 6. [The treatment of anemia in patients with terminal renal insufficiency in haemodialysis. Working hypothesis and preliminary results (author's transl)].
    Escribano Mora L; Sanz Guajarado A; García de Bustos JM; Sánchez Sicilia L; Torre Carballada A; Martínez Ara J; Gómez Fernández P; Selgas Guítierrez R; Martín Villar J
    Sangre (Barc); 1980; 25(5B):688-96. PubMed ID: 7466551
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of anemia in patients with chronic renal disease: is it time for self-criticism?].
    Del Vecchio L
    G Ital Nefrol; 2007; 24(4):285. PubMed ID: 17659497
    [No Abstract]   [Full Text] [Related]  

  • 8. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease.
    Singh AK; Hertello P
    Nephrol Nurs J; 2005; 32(2):199-206; quiz 207-8. PubMed ID: 15889804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a vitamin E-bonded membrane and of glutathione on anemia and erythropoietin requirements in hemodialysis patients.
    Usberti M; Gerardi G; Micheli A; Tira P; Bufano G; Gaggia P; Movilli E; Cancarini GC; De Marinis S; D'Avolio G; Broccoli R; Manganoni A; Albertin A; Di Lorenzo D
    J Nephrol; 2002; 15(5):558-64. PubMed ID: 12455724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron metabolism in haemodialysis patients. A study of the management of iron therapy and overload.
    Gokal R; Millard PR; Weatherall DJ; Callender ST; Ledingham JG; Oliver DO
    Q J Med; 1979 Jul; 48(191):369-91. PubMed ID: 542584
    [No Abstract]   [Full Text] [Related]  

  • 11. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
    Singh A
    Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous iron therapy in renal failure: friend and foe?
    Afzali B; Goldsmith DJ
    J Nephrol; 2004; 17(4):487-95. PubMed ID: 15372409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Etiopathogenic mechanisms of anemia in hemodialysis patients].
    Marco Franco JE; Alarcón Zurita A; Dalmau Diana M; Pizá Buñola C; Morey Molina A; Bestard Palmer J; Mairata Bosch S; Ribas Mundó M
    Rev Clin Esp; 1983 Jan; 168(2):83-5. PubMed ID: 6344155
    [No Abstract]   [Full Text] [Related]  

  • 15. [Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis?].
    Pérez-García R; Rodríguez-Benítez P; Villaverde MT; Valderrábano F
    Nefrologia; 2001; 21(6):606-7. PubMed ID: 11881433
    [No Abstract]   [Full Text] [Related]  

  • 16. Caring for the renal failure patient: optimizing iron therapy.
    Folkert VW; Javier AM; O'Mara NB
    Nephrol Nurs J; 2002 Dec; 29(6):586-93; quiz 594-5. PubMed ID: 12596608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

  • 18. [Anemia and progression of renal failure].
    Gellert R
    Pol Arch Med Wewn; 2002 Apr; 107(4):375-7. PubMed ID: 12189930
    [No Abstract]   [Full Text] [Related]  

  • 19. Hemoglobin levels, quality of life, and survival.
    Sadler JH; Meyer KB
    Nephrol News Issues; 2007 Aug; 21(9):42-3. PubMed ID: 17722853
    [No Abstract]   [Full Text] [Related]  

  • 20. [What are the aims and targets of renal anemia therapy?].
    Eckardt KU
    Dtsch Med Wochenschr; 2007 Sep; 132(36):1837-41. PubMed ID: 17726657
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.